Molecular Medicine Tri-Conference              Pek Yee Lum, Ph.D.                 VP Life Sciences
Today’s AgendaWhat are the problems we face in drug discovery anddevelopment?How can Ayasdi uniquely solve the problems?Wh...
Today’s AgendaWhat are the problems we face in drug discovery anddevelopment?How can Ayasdi uniquely solve the problems?Wh...
Big data, bigger problems       for drug discovery and development       • Ever-growing complex and disparate datasets    ...
Data analysis landscape today                                                                   R                         ...
Biological Complexity on top of       data problems       Diseases are often complex. Many components work in synergy     ...
Today’s AgendaWhat are the problems we face in drug discovery anddevelopment?How can Ayasdi uniquely solve the problems?Wh...
Ayasdi Iris increases probability of success (POS) and         shrinks time to market         Discovery of subtle patterns...
Today’s AgendaWhat are the problems we face in drug discovery anddevelopment?How can Ayasdi uniquely solve the problems?Wh...
Solution Math+CS+UX platform          Data has Shape                      Shape has meaningData has shape         © 2012 A...
What is shape ?       If Age, Weight and Height were                 In reality, age, weight and height are       distribu...
What is shape ?     Ayasdi Iris identifies the shape or pattern in dataData has shape            © 2012 Ayasdi inc.
Why Topological Data Analysis       for drug discovery and development       1. Coordinate free representations are vital ...
Ayasdi Iris           Uses principles of geometry to find shape (pattern)           in data           Works across and for ...
Today’s AgendaWhat are the problems we face in drug discovery anddevelopment?How can Ayasdi uniquely solve the problems?Wh...
Patient stratification - Results        gene expression profiling of breast tumors        Identified a sub-group of patients ...
Each node contains                                                    subsets of patients                                 ...
High event death                                                     Low event death                        Mixed event de...
patients did not survive 10 yrs                                                                 B                         ...
NKI data                       high ESR1 death                                                  low ESR1 survived         ...
Conventional Methods                       subtypes difficult to identify                                   Clustering      ...
Today’s AgendaWhat are the problems we face in drug discovery anddevelopment?How can Ayasdi uniquely solve the problems?Wh...
Ayasdi Iris platform                                       Ayasdi Iris Life Sciences Edition                              ...
Ayasdi Iris increases probability of success (POS) and         shrinks time to market         Discovery of subtle patterns...
Contact us for more informationwww.ayasdi.compek@ayasdi.com         Get this talk on our complimentary USBperry@ayasdi.com...
Upcoming SlideShare
Loading in...5
×

2012 Big Data - Bigger Problems for Drug Discovery and Development

465

Published on

Published in: Health & Medicine
0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total Views
465
On Slideshare
0
From Embeds
0
Number of Embeds
1
Actions
Shares
0
Downloads
0
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide

Transcript of "2012 Big Data - Bigger Problems for Drug Discovery and Development"

  1. 1. Molecular Medicine Tri-Conference Pek Yee Lum, Ph.D. VP Life Sciences
  2. 2. Today’s AgendaWhat are the problems we face in drug discovery anddevelopment?How can Ayasdi uniquely solve the problems?Why topology?Patient stratification using topologySummary © 2012 Ayasdi inc.
  3. 3. Today’s AgendaWhat are the problems we face in drug discovery anddevelopment?How can Ayasdi uniquely solve the problems?Why topology?Patient stratification using topologySummary © 2012 Ayasdi inc.
  4. 4. Big data, bigger problems for drug discovery and development • Ever-growing complex and disparate datasets • Scalability issues • NGS raw data sometimes as large as 1TB per sample • Accessing data no longer simple for the untrained users • New IT infrastructure for every new problem • Every new data type needs custom tools • User experience does not exist today • Bioinformatics tools are not integrated • Analysis and visualization is disparate • Accelerating the discovery process requires rethinking the analysis workflow and streamlining its computational infrastructureProblems in drug discovery and development © 2012 Ayasdi inc.
  5. 5. Data analysis landscape today R Cytoscape Database Spotfire Matlab Math Writing code CloudProblems in drug discovery and development © 2012 Ayasdi inc.
  6. 6. Biological Complexity on top of data problems Diseases are often complex. Many components work in synergy for disease manifestation. The need to identify perhaps not a single drug target but multiple targets that work as a network Human population is heterogenous- drugs fail because of the inability to stratify the patient population The need to identify biomarkers that work for patient stratification to decrease risk of adverse events and lack of efficacyProblems in drug discovery and development © 2012 Ayasdi inc.
  7. 7. Today’s AgendaWhat are the problems we face in drug discovery anddevelopment?How can Ayasdi uniquely solve the problems?Why topology?Patient stratification using topologySummary © 2012 Ayasdi inc.
  8. 8. Ayasdi Iris increases probability of success (POS) and shrinks time to market Discovery of subtle patterns in a sea of noisy data Handling of all data- large or small on the cloud Fusing disparate data sets with ease Access to critical public data on demand Allows collaboration for all types of stakeholders on one platformThe Ayasdi solution © 2012 Ayasdi inc.
  9. 9. Today’s AgendaWhat are the problems we face in drug discovery anddevelopment?How can Ayasdi uniquely solve the problems?Why topology?Patient stratification using topologySummary © 2012 Ayasdi inc.
  10. 10. Solution Math+CS+UX platform Data has Shape Shape has meaningData has shape © 2012 Ayasdi inc.
  11. 11. What is shape ? If Age, Weight and Height were In reality, age, weight and height are distributed randomly correlated and that data has a shapeData has shape © 2012 Ayasdi inc.
  12. 12. What is shape ? Ayasdi Iris identifies the shape or pattern in dataData has shape © 2012 Ayasdi inc.
  13. 13. Why Topological Data Analysis for drug discovery and development 1. Coordinate free representations are vital when studying data collected using different technologies- lots of public data available, many studies done at different times, different data types collected 2. Deformation invariance has an effect of introducing robustness into the analysis, which is important in the study of real world data- biological heterogeneity is complex and needs an approach that is deformation (variation) resistant 3. Compressed representations are obviously important when one is dealing with very large data sets- with high dimensional omics data and Next Gen sequencing getting more affordable, the amount of data is increasing exponentiallyWhy topology ? © 2012 Ayasdi inc.
  14. 14. Ayasdi Iris Uses principles of geometry to find shape (pattern) in data Works across and for any type of data Works with any amount of data Generates and validates hypotheses Quick, interactive resultsWhy topology ? © 2012 Ayasdi inc.
  15. 15. Today’s AgendaWhat are the problems we face in drug discovery anddevelopment?How can Ayasdi uniquely solve the problems?Why topology?Patient stratification using topologySummary © 2012 Ayasdi inc.
  16. 16. Patient stratification - Results gene expression profiling of breast tumors Identified a sub-group of patients that are triple negative with very good prognosis Identified a sub-group of patients that are Luminal A but with perfect survival (published PNAS 2011) These groups were identified in independent datasets These sub-groups were hard to find using conventional methodsPatient stratification © 2012 Ayasdi inc.
  17. 17. Each node contains subsets of patients These patients are eccentric (away from the center of the data) These patients are close to the center of the data Color scheme Topological Map of Patient-Patient Relationships according to the molecular characteristics of their tumors (in this case, gene expression)Patient stratification © 2012 Ayasdi inc.
  18. 18. High event death Low event death Mixed event death These patients are eccentric (away from the center of the data) Zero event death Color scheme Color schemePatient stratification Zero event death © 2012 Ayasdi inc.
  19. 19. patients did not survive 10 yrs B D E A Triple Negative HER2-, ESR-, PGR- C patients survived 10 yrsPatient stratification © 2012 Ayasdi inc.
  20. 20. NKI data high ESR1 death low ESR1 survived high ESR1 low ESR1 Topological maps from GSE2304 two independent cancer data sets are very relapsed low ESR1 similar high ESR1relapse no high ESR1 low ESR1 © 2012 Ayasdi inc.
  21. 21. Conventional Methods subtypes difficult to identify Clustering PCA ER- did not surviveER- survivedPatient stratification © 2012 Ayasdi inc.
  22. 22. Today’s AgendaWhat are the problems we face in drug discovery anddevelopment?How can Ayasdi uniquely solve the problems?Why topology?Patient stratification using topologySummary © 2012 Ayasdi inc.
  23. 23. Ayasdi Iris platform Ayasdi Iris Life Sciences Edition PubMed All analyses performed on the GO KEGG PPI GEO cloud on secure servers Interactive Network Integrated Statistics Integrated Public Bypass the need to invest in Visualization Algorithms Datasets Ayasdi Iris Cloud Platform expensive hardware and Analysis and Visualization Topological Mapping Network Analysis Projections (e.g. PCA) Network Visualization Histograms/ Scatterplots Dendro- grams database administration Flexibility to start your analysis Scalable Distributed Datastore immediately- just upload your data Access to public data on Proprietary and Public data sources Gene Expression mRNA SNP Clinical NGS PubMed demandAyasdi Iris platform © 2012 Ayasdi inc.
  24. 24. Ayasdi Iris increases probability of success (POS) and shrinks time to market Discovery of subtle patterns in a sea of noisy data Handling of all data- large or small on the cloud Fusing disparate data sets with ease Access to critical public data on demand Allows collaboration for all types of stakeholders on one platformThe Ayasdi solution © 2012 Ayasdi inc.
  25. 25. Contact us for more informationwww.ayasdi.compek@ayasdi.com Get this talk on our complimentary USBperry@ayasdi.com Please stop by our poster :Core Poster #10

×